[Treatment of schizophrenia in subjects with substance use disorders: A review]
- PMID: 11333531
[Treatment of schizophrenia in subjects with substance use disorders: A review]
Abstract
Background: Schizophrenic patients have a high comorbidity with substance use disorders. However, there are few studies on the efficacy of antipsychotics on psychopathology and on their repercutions on substance abuse.
Methods: All studies about pharmacological treatment of schizophrenic patients with substance abuse, included in Medline over the last ten years were analyzed.
Results: Of the 17 studies reviewed, most were prospective with small samples (< 30 patients, 5 studies) or case reports (7 studies). Objectives were to assess the efficacy on schizophrenic symptoms and the effect of the treatment on substance use. Atypical antipsychotics were the most studied. These pharmacological agents were effective at reducing symptoms and had few side effects. They also managed lo reduce substance abuse in 66-75% of patients.
Conclusions: In spite of underlyng methodological problems of these studies, the findings suggest that atypical antipsychatics could be the treatment of choice in these patients.
Similar articles
-
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.Am J Psychiatry. 2002 Feb;159(2):255-62. doi: 10.1176/appi.ajp.159.2.255. Am J Psychiatry. 2002. PMID: 11823268 Clinical Trial.
-
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.Am J Psychiatry. 2002 Jun;159(6):1018-28. doi: 10.1176/appi.ajp.159.6.1018. Am J Psychiatry. 2002. PMID: 12042192 Clinical Trial.
-
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.Am J Psychiatry. 2003 Feb;160(2):290-6. doi: 10.1176/appi.ajp.160.2.290. Am J Psychiatry. 2003. PMID: 12562575 Clinical Trial.
-
[Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients].Fortschr Neurol Psychiatr. 2002 Mar;70(3):139-44. doi: 10.1055/s-2002-20501. Fortschr Neurol Psychiatr. 2002. PMID: 11880946 Review. German.
-
Olanzapine and the new generation of antipsychotic agents: patterns of use.J Clin Psychiatry. 1997;58 Suppl 10:18-21. J Clin Psychiatry. 1997. PMID: 9265912 Review.
Cited by
-
(AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population.Eur Arch Psychiatry Clin Neurosci. 2006 Oct;256(7):437-41. doi: 10.1007/s00406-006-0665-3. Epub 2006 Jun 20. Eur Arch Psychiatry Clin Neurosci. 2006. PMID: 16788767
-
Potential benefits of quetiapine in the treatment of substance dependence disorders.J Psychiatry Neurosci. 2004 Nov;29(6):452-7. J Psychiatry Neurosci. 2004. PMID: 15644986 Free PMC article.